Feehally J
Department of Nephrology, Leicester General Hospital, UK.
Curr Opin Nephrol Hypertens. 1996 Sep;5(5):442-6.
There is no specific treatment to reduce glomerular IgA deposition in IgA nephropathy. The available controlled trials are restricted to patients with proteinuria and progressive renal failure where mechanisms of injury are common to other chronic glomerular diseases. Control of blood pressure is vital, but there is no conclusive evidence that angiotensin-converting enzyme inhibitors are the agents of choice. Fish oil appears to be beneficial, but the available trial data are not entirely consistent. Immunosuppressive regimens based on corticosteroids and cytotoxic agents may be beneficial, but there is concern over long-term toxicity. Angiotensin-converting enzyme gene polymorphisms may identify cohorts who are at special risk of progressive renal failure for recruitment into future trials.
在IgA肾病中,尚无特异性治疗方法可减少肾小球IgA沉积。现有的对照试验仅限于蛋白尿和进行性肾衰竭患者,这些患者的损伤机制与其他慢性肾小球疾病相同。控制血压至关重要,但尚无确凿证据表明血管紧张素转换酶抑制剂是首选药物。鱼油似乎有益,但现有的试验数据并不完全一致。基于皮质类固醇和细胞毒性药物的免疫抑制方案可能有益,但人们担心其长期毒性。血管紧张素转换酶基因多态性可能有助于识别有进行性肾衰竭特殊风险的人群,以便纳入未来的试验。